Atara Biotherapeutics Inc (ATRA)
NASDAQ:ATRA
Top Page
Atara Biotherapeutics
(NASDAQ:ATRA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▼(-71.50% Downside)
Action:ReiteratedDate:03/17/26
The score is weighed down primarily by weak financial quality (negative free cash flow and negative equity) and significant regulatory uncertainty around EBVALLO. Technicals are only modestly supportive in the very near term, while valuation support is limited due to a negative P/E and no dividend.
Positive Factors
Allogeneic T‑cell Platform
Atara’s strategic focus on off-the-shelf allogeneic T‑cell therapies is a durable business model advantage: such platforms can scale manufacturing, reduce per-patient cost versus autologous approaches, and address multiple oncology and viral-driven indications, supporting structural commercial optionality if clinical and regulatory milestones are met.
Negative Factors
Negative Shareholders' Equity
Sustained negative equity is a material capitalization issue reflecting cumulative losses and balance-sheet erosion. It constrains financial flexibility, can increase the cost of capital, and typically forces dilution or unfavorable financing terms to fund operations, posing a durable headwind to rebuilding a stable capital base absent sustained profits or major asset infusions.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic T‑cell Platform
Atara’s strategic focus on off-the-shelf allogeneic T‑cell therapies is a durable business model advantage: such platforms can scale manufacturing, reduce per-patient cost versus autologous approaches, and address multiple oncology and viral-driven indications, supporting structural commercial optionality if clinical and regulatory milestones are met.
Read all positive factors
Atara Biotherapeutics (ATRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.83M
Dividend YieldN/A
Average Volume (3M)388.52K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth51.27%
EPS GrowthN/A
CountryUS
Employees153
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding8,178,114
10 Day Avg. Volume66,890
30 Day Avg. Volume388,517
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap2.11
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda2.26
Forecast
1Y Price Target
$12.00Price Target Upside-24.00% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$16.27M
Atara Biotherapeutics Business Overview & Revenue Model
Company Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 c...
How the Company Makes Money
Atara Biotherapeutics has historically generated revenue primarily from collaboration and licensing arrangements rather than from large-scale product sales, reflecting its clinical-stage profile. Key revenue streams typically include (1) collabora...
Atara Biotherapeutics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 120.77M | 128.94M | 8.57M | 63.57M | 20.34M |
| Gross Profit | 99.56M | 107.93M | -313.00K | 63.57M | -261.66M |
| EBITDA | 50.41M | -75.75M | -266.00M | -222.26M | -331.12M |
| Net Income | 32.69M | -85.40M | -276.13M | -228.30M | -340.14M |
Balance Sheet | |||||
| Total Assets | 20.23M | 109.10M | 165.50M | 376.42M | 468.13M |
| Cash, Cash Equivalents and Short-Term Investments | 8.48M | 42.50M | 51.73M | 242.82M | 371.07M |
| Total Debt | 52.80M | 43.83M | 57.87M | 71.70M | 28.27M |
| Total Liabilities | 58.74M | 206.38M | 264.74M | 249.78M | 188.51M |
| Stockholders Equity | -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash Flow | |||||
| Free Cash Flow | -50.94M | -68.96M | -194.20M | -274.62M | -231.10M |
| Operating Cash Flow | -50.94M | -68.72M | -192.98M | -270.43M | -220.52M |
| Investing Cash Flow | 18.15M | 8.62M | 123.87M | 202.96M | 22.26M |
| Financing Cash Flow | 16.10M | 59.28M | 2.01M | 53.08M | 103.94M |
Atara Biotherapeutics Technical Analysis
Negative
15.79
Price Trends
5.08
Negative
9.39
Negative
10.71
Negative
Market Momentum
-0.24
Negative
45.37
Neutral
67.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 15.79 is above the 20-day moving average (MA) of 5.34, above the 50-day MA of 5.08, and above the 200-day MA of 10.71, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 45.37 is Neutral, neither overbought nor oversold. The STOCH value of 67.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.
Atara Biotherapeutics Risk Analysis
Atara Biotherapeutics disclosed 64 risk factors in its most recent earnings report. Atara Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atara Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $190.80M | -0.71 | -52.77% | ― | -33.76% | 17.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $59.18M | -1.00 | -71.28% | ― | -10.03% | 11.06% | |
47 Neutral | $314.74M | -0.23 | ― | ― | -63.96% | -28.50% | |
43 Neutral | $202.11M | -1.36 | -120.20% | ― | -9.70% | 23.23% | |
42 Neutral | $39.83M | -16.66 | -79.12% | ― | 51.27% | ― |
* Healthcare Sector Average
ATRA
Atara Biotherapeutics
4.87
-0.86
-15.01%
MGNX
MacroGenics
3.18
2.08
189.09%
ZNTL
Zentalis Pharmaceuticals
2.69
1.53
131.90%
SRZN
Surrozen
27.40
17.60
179.59%
TCRX
TScan Therapeutics
1.04
-0.22
-17.46%
Atara Biotherapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Atara Plans FDA Type A Meeting on EBVALLO
Neutral
Mar 12, 2026
On March 12, 2026, Atara Biotherapeutics announced that it has scheduled a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued on January 9, 2026, for the Biologics License Application of its pr...
Product-Related AnnouncementsRegulatory Filings and Compliance
Atara, Pierre Fabre seek FDA meeting on EBVALLO
Negative
Mar 3, 2026
On March 3, 2026, Atara Biotherapeutics reported that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the U.S. Food and Drug Administration to address issues raised in the Complete Response Letter issued on January 9, ...
Business Operations and StrategyPrivate Placements and Financing
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant
Positive
Feb 23, 2026
On February 20, 2026, Atara Biotherapeutics amended its existing Purchase and Sale Agreement with a fund managed by HealthCare Royalty, pushing back a one-time $9.0 million milestone payment tied to its Pierre Fabre commercialization deal from Jun...
Business Operations and StrategyFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
Negative
Jan 12, 2026
On January 12, 2026, Atara Biotherapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter for EBVALLO (tabelecleucel), rejecting its Biologics License Application as a monotherapy for EBV-positive post-transp...
Business Operations and Strategy
Atara revises tab-cel commercialization milestones with Pierre Fabre
Neutral
Jan 2, 2026
On December 30, 2025, Atara Biotherapeutics amended its commercialization agreement with Pierre Fabre Medicament, reducing potential regulatory milestone payments tied to FDA approval of a BLA for tab-cel from $40 million to $31 million in exchang...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.